Abstract: There are provided a storage device and an operating method thereof. The storage device includes: a memory device including a plurality of memory blocks, a buffer memory configured to temporarily store data, and a memory controller configured to, in response to occurrence of a power loss, generate address information including logical addresses of write data that correspond to the data temporarily stored in the buffer memory and meta data, and control the memory device to store the address information and the write data in a predetermined backup block group included in the plurality of memory blocks.

Abstract: A memory system may write, when operating in a force unit access mode, first write data requested by the host to a buffer for temporarily storing data to be written the memory device and a first memory block among the plurality of memory blocks, and may write, when the size of the data accumulatively stored in the buffer is greater than or equal to A which is a unit of a size in which data is written to a second memory block among the plurality of memory blocks, second write data of size A among the data stored in the buffer to the second memory block. The operation speed of the first memory block may be set faster than the operation speed of the second memory block and the storage capacity of the first memory block may be set smaller than the storage capacity of the second memory block.

Abstract: A method of producing a hair-dyeing composition kit includes providing a first composition including from 5 to 30% by weight of a first base material containing polyoxyethylene octyl ether phosphate and polyoxyethylene oleyl ether phosphate, and an auxiliary constituent of cetearyl alcohol, behenyl alcohol, mineral oil, and mixtures thereof; from 5 to 25% by weight of an alkalizing agent of monoethanolamine, ammonia water having a concentration of 28% by weight, and mixtures thereof; from 0.01 to 2% by weight of a color developer; and a first solvent; and providing a second composition including from 1 to 10% by weight of a second base material of polyoxyethylene oleyl ether phosphate, cetearyl alcohol, and mixtures thereof; from 12 to 20% by weight of an oxidizing agent; from 0.1 to 1% by weight of a pH adjusting agent; and a second solvent. The first the second compositions are combined in use.

Abstract: A hair-dyeing composition with an effect of minimizing hair damage and scalp irritation caused by ammonia prescription and ammonia odor is capable of decreasing ammonia odor peculiar to a hair-dyeing composition and also of supplementing the hair with amino acids similar to hair proteins to decrease hair damage, especially hair roughness and hair shortening, for healthy dyeing and a method of producing the same.

Abstract: A hair-dyeing composition that minimizes hair damage and scalp irritation caused by applying ammonia to the scalp and that reduces the ammonia odor peculiar to hair-dyeing compositions is provided. The hair-dyeing composition additionally supplements the hair with amino acids similar to hair proteins to decrease hair damage, especially hair roughness and hair shortening, for healthy dyeing. A method of producing the hair-dyeing composition is additionally provided and includes melting, mixing, and emulsifying steps.

Abstract: Provided is a chemically modified targeting protein, a pharmaceutical composition including the chemically modified targeting protein, a conjugate including the chemically modified targeting protein and a drug, and methods for preparing the same.

Abstract: A hair-dyeing composition with an effect of minimizing hair damage and scalp irritation caused by ammonia prescription and ammonia odor is capable of decreasing ammonia odor peculiar to a hair-dyeing composition and also of supplementing the hair with amino acids similar to hair proteins to decrease hair damage, especially hair roughness and hair shortening, for healthy dyeing and a method of producing the same.

Abstract: A three-helix bundle protein, a polynucleotide encoding the three-helix bundle protein, a method of preparing the three-helix bundle protein, and a method of treating a cancer using the three-helix bundle protein.

Abstract: A protein complex comprising a first polypeptide comprising a first antigen-binding region; a second polypeptide comprising a second antigen-binding region; and a linker connecting the first polypeptide and the second polypeptide, wherein the first antigen-binding region is a single stranded polypeptide comprising a first light chain antigen-binding region and a first heavy chain antigen-binding region, the second antigen-binding region is a single stranded polypeptide comprising a second light chain antigen-binding region and a second heavy chain antigen-binding region, and the linker connects the C-terminal of the first polypeptide and the N-terminal of the second polypeptide, and comprises a tag including a cleavable amino acid sequence at one terminal or both terminals of the linker; as well as a bispecific antibody derived from the protein complex, and related compositions and methods.

Abstract: A protein complex including at least two monoclonal antibodies is provided. By using the protein complex, a system for simultaneously targeting at least two antigens is effectively constructed.

Abstract: In one example embodiment of the inventive concepts, an adaptive data backup method performed in a memory system including a non-volatile multi-level cell memory device includes receiving a write command from a host and determining a backup data size which is a size of data to be backed up among data requested to be written in the write command. The adaptive data backup method further includes selecting a backup type among at least two different backup types, based on the backup data size and backing up the data according to the selected backup type.

Abstract: A fusion protein including granzyme B, a cell penetrating peptide, a cleavage site, and a targeting moiety, a composition for cell membrane penetration comprising the fusion protein, and an anticancer composition comprising the fusion protein.

Abstract: The disclosure provides novel chemical compounds represented by Formula I or a pharmaceutically acceptable salt, solvate, polymorph, ester, tautomer or prodrug thereof. The compounds can be used as an inhibitor of Trk and are useful in the treatment of pain, cancer, inflammation, neurodegenerative disease and certain infectious diseases.

Abstract: An apparatus for cooling a spent fuel pool having a heat exchanger includes a cooling water pool positioned above the spent fuel pool; a floating device configured to be elevated according to a water level of a cooling water in the spent fuel pool; and an emergency cooling water supply pipe configured to form a path through which the cooling water of the cooling water pool is moved to the spent fuel pool and configured to include a floating valve that opens or closes a flow passage of the cooling water in connection with the elevation of the floating device.

Abstract: A fusion protein including a targeting moiety, a cleavage site, and a cell membrane penetrating domain, a conjugate including the fusion protein and a bioactive molecule, and methods employing the fusion protein and the conjugate are provided.

Abstract: A p16 protein variant; a polynucleotide encoding the p16 protein variant; a method for preparing the p16 protein variant; a pharmaceutical composition comprising the p16 protein variant; a method for preventing and/or treating cancer comprising administering the p16 protein variant to a subject; and use of the p16 protein variant in the prophylaxis and/or therapy of cancer.

Abstract: A polypeptide binding to Annexin A1, an antagonist against Annexin A1 including the polypeptide, an anti-Annexin A1 antibody including the polypeptide or an antigen-binding fragment thereof, and methods of preventing, treating and/or diagnosing a disease, including administering the antagonist and/or the antibody or an antigen-binding fragment thereof to a subject.

Abstract: A protein complex comprising (i) a first fusion protein comprising (a) a first polypeptide that comprises a first antigen-binding site and (b) a first binding protein linked to a terminus of the first polypeptide; and (ii) a second fusion protein comprising (a) a second polypeptide that comprises a second antigen-binding site and (b) a second binding protein linked to a terminus of the second polypeptide, wherein the protein complex comprises an amino acid sequence that enables cleavage between the first polypeptide and the first binding protein, and/or between the second polypeptide and the second binding protein, as well as a method for preparing a bi-specific antibody and related methods and compositions.

Abstract: A p15 protein variant; a polynucleotide encoding the p15 protein variant; a method for preparing the p15 protein variant; a pharmaceutical composition comprising the p15 protein variant; and a method for preventing and/or treating cancer comprising administering the p15 protein variant to a subject.

Abstract: A three-helix bundle protein, a polynucleotide encoding the three-helix bundle protein, a method of preparing the three-helix bundle protein, and a method of treating a cancer using the three-helix bundle protein.